GlassScriptPhysician profile
Neil E Crittenden
NPI 1598907115
$2,747.91
in general payments reported to CMS, 2019-2025
27 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.18 · 2020: $111 · 2021: $125 · 2022: $147 · 2024: $57.05 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.83 | 2019-2025 | |
| Janssen Biotech, INC. | $197.88 | 2021-2025 | Tremfya |
| Medtronic, INC. | $197.01 | 2025 | Interstim |
| Lilly USA, LLC | $175.27 | 2025 | Omvoh |
| Genzyme Corporation | $170.08 | 2025 | |
| Gilead Sciences, INC. | $166.85 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.65 | 2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $124.13 | 2019-2025 | |
| Madrigal Pharmaceuticals | $102.96 | 2025 | Rezdiffra |
| Qol Medical, LLC | $101.28 | 2025 | Sucraid |
| Celltrion USA INC. | $83.56 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $82.96 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $68.41 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $54.53 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $24.49 | 2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $23.53 | 2025 | Stelara, Tremfya |
| Amgen INC. | $21.80 | 2025 | Uplizna |
| Dynavax Technologies Corporation | $20.89 | 2025 | Heplisav-B |
| Pharmacosmos Therapeutics INC. | $19.59 | 2025 | Monoferric |
| Ardelyx, INC. | $19.59 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $19.15 | 2025 | |
| Novo Nordisk INC | $18.68 | 2025 | Wegovy |
| Micro-Tech Endoscopy USA, INC. | $9.41 | 2024 | Lesionhunter |
| Romark Laboratories, Lc | $3.38 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Crittenden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.